© Globe Newswire
21.03.2025
TRAW
LISTED
NASDAQ
Traws Pharma’s Bird Flu Drug Candidate, Tivoxavir Marboxil, Presented at ICAR
News Preview
NEWTOWN, Pa., March 21, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced that positive data supporting the potential for tivoxavir m...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.03.2025
ORNBV
LISTED
HEL
Pharmaceutical industry delivers value proposition to Finnish Government: billions to be invested by 2030
News Preview
ORION CORPORATION PRESS RELEASE 21 MARCH 2025 at 13:00 EET...
Themefolio
Profiler
Peergroup
© Newsfile
21.03.2025
COPN
LISTED
SIX
Cosmo Pharmaceuticals publishes Annual Report 2024
News Preview
Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland--(Newsfile Corp. - March 21, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) has published today its Annual Report for the fiscal year ending December 31, 2024. As already outlined in the unaudited 2024 Full-Year results on March...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Globe Newswire
21.03.2025
KDEV
LISTED
STO
Karolinska Development Annual Report 2024 published
News Preview
STOCKHOLM, SWEDEN – March 21, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces publication of its Annual Report 2024....
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
21.03.2025
UCB
LISTED
EURONEXT
UCB Convening Notice to the General Meeting of the Shareholders 2025
News Preview
CONVENING NOTICE TO THE GENERAL MEETING OF SHAREHOLDERS...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
21.03.2025
CLBX
LISTED
AIMX
Angle PLC Announces Issue of LTIP Options and Share Options
News Preview
GUILDFORD, SURREY / ACCESS Newswire / March 21, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, announces that, under the Remuneration Policy approved by the shareholders at the Annual General Meeting on 11 July 2024 ("the Remuneration Policy"), the Remuneration Committee has approved the grant under the Lo...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
21.03.2025
CLBX
LISTED
AIMX
Angle PLC Announces Results of Eisai Phase 2 pilot study
News Preview
UPDATE ON ASTRAZENECA ASSAY DEVELOPMENT PROJECTS AND SUCCESSFUL COMPLETION OF EISAI CONTRACTDevelopment of both the prostate cancer androgen receptor assay and the multi-cancer DDR micronuclei assay successfully completed for AstraZenecaResults of Eisai Phase 2 pilot study supports the capability of the Parsortix system for real-time assessment of...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.03.2025
GNFT
LISTED
EURONEXT
GENFIT Announces Completion of Non-dilutive Royalty Financing Agreement with HCRx and Results of Repurchase Offer to 2025 OCEANEs holders
News Preview
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), March 20, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases (the “Company”), is pleased to announce the successful completion of its royalty financing transac...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.03.2025
SKYE
LISTED
NASDAQ
Skye Bioscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
News Preview
SAN DIEGO, March 20, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ: SKYE) (“Skye” or the “Company”), a clinical stage biopharmaceutical company pioneering next-generation molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related conditions, today reported financial results for the fourth quarter and fu...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.03.2025
ZEAL
LISTED
CPH
Zealand Pharma increases its share capital as a result of the exercise of employee warrants
News Preview
Company announcement – No. 5 / 2025...
Themefolio
Profiler
Peergroup
© EQS Newswire
20.03.2025
EUZ
LISTED
XETR
Eckert & Ziegler und AtomVie Global Radiopharma unterzeichnen weltweite Vereinbarung über die Lieferung von Lutetium-177
News Preview
Berlin, DE & Hamilton, ON, CA, 20. März 2025. Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) und AtomVie Global Radiopharma Inc. (AtomVie) haben heute eine globale Liefervereinbarung bekannt gegeben. Eckert & Ziegler wird sein trägerfreies, qualitativ hochwertiges Lutetium-177-Chlorid (n.c.a. Lu-177, Theralugand®) zur Unterstützung der......
Themefolio
Profiler
Peergroup
© EQS Newswire
20.03.2025
EUZ
LISTED
XETR
Eckert & Ziegler and AtomVie Global Radiopharma Sign a Global Agreement for Lutetium-177 Supply
News Preview
Berlin, DE & Hamilton, ON, CA, 20 March 2025. Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) and AtomVie Global Radiopharma Inc. (AtomVie) today announced a global supply agreement. Eckert & Ziegler will provide its high-quality non-carrier added Lutetium-177 chloride (n.c.a. Lu-177, Theralugand®) to support AtomVie’s CDMO activities f......
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
20.03.2025
ORNBV
LISTED
HEL
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
News Preview
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS20 MARCH 2025 at 15.30 EET ...
Themefolio
Profiler
Peergroup
© PR Newswire
20.03.2025
ATNM
LISTED
XASE
Actinium Pharmaceuticals Announces Research Collaboration with Memorial Sloan Kettering to Support Further Clinical Expansion of Actimab-A's Backbone Therapy Strategy
News Preview
NEW YORK, March 20, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced that is has entered into a sponsored research agreement with Memorial Sloan Kettering Cancer Center (MSKCC) to expand Actimab-A's mutation agnostic mechan...
Themefolio
Profiler
Peergroup
© BusinessWire
20.03.2025
SLP
LISTED
NASDAQ
Simulations Plus Announces Second Quarter Fiscal Year 2025 Earnings and Conference Call Date
News Preview
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that it will report second quarter fiscal 2025 financial results after the market close on Thursday,...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.03.2025
AUTL
LISTED
NASDAQ
Autolus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
News Preview
Autolus announces recent updates and financial results for the full year ended December 31, 2024....
Themefolio
Profiler
Peergroup
© Globe Newswire
20.03.2025
POAI
LISTED
NASDAQ
Predictive Oncology Completes Sale of Skyline Medical Assets to DeRoyal Industries
News Preview
Deal positions STREAMWAY® Systems with an established market leader to drive accelerating growth...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.03.2025
IBAB
LISTED
EURONEXT
IBA reports solid Full Year 2024 results
News Preview
Read the entire full year 2024 results press release here...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.03.2025
GN
LISTED
CPH
Trading in GN Store Nord shares by board members, executives and associated persons
News Preview
GN Store Nord has received notification pursuant to article 19 of regulation (EU) no. 596/2014 of the below transactions related to shares in GN Store Nord made by persons discharging managerial responsibilities in GN Store Nord and/or persons closely associated with them....
Themefolio
Profiler
Peergroup
© PR Newswire
19.03.2025
ATNM
LISTED
XASE
Actinium Pharmaceuticals to Host Investor KOL Call with Dr. Ehab Atallah of the Medical College of Wisconsin and Provide a Pipeline Update Highlighting Revamped Clinical Programs and Expanded Market Opportunities for Actimab-A and Iomab-ACT with Clinical
News Preview
- Actinium to highlight 3 separate multi-billion-dollar market opportunities for Actimab-A and Iomab-ACT in myeloid malignancies, solid tumors and cell & gene therapy conditioning
- Clinical proof of concept data expected in 2H:2025 from Actimab-A combination with blockbuster immunotherapies KEYTRUDA® and OPDIVO® in solid tumor indicati...
Themefolio
Profiler
Peergroup
© PR Newswire
19.03.2025
IMMNOV
LISTED
STO
Immunovia announces another successful clinical validation of its next-generation pancreatic cancer test
News Preview
LUND, Sweden, March 19, 2025 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced positive results from the VERIFI study, the second clinical validation study of its next-generation pancreatic cancer test. The study met its primary endpoint, with the test successfully detecting 77% of st...
Themefolio
Profiler
Peergroup
© PR Newswire
19.03.2025
SOBI
LISTED
STO
Sobi announces a new research collaboration on the development of Gamifant® (emapalumab) in sepsis, which is to be presented at the ISICEM congress
News Preview
STOCKHOLM, March 19, 2025 /PRNewswire/ -- Sobi® (STO: SOBI), today announced a research collaboration involving a new Phase 2a clinical trial for Gamifant® (emapalumab) for the potential treatment of interferon-gamma (IFNγ)-driven sepsis (IDS) which is to be presented at the International Symposium on Intensive Care and Emergency Medicine (ISICEM...
Themefolio
Profiler
Peergroup
© PR Newswire
18.03.2025
RAY B
LISTED
STO
Completed placing of shares in RaySearch Laboratories AB (publ)
News Preview
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE OR MAY BE UNLAWFUL. PLEASE REFER TO THE SECTION "IMPORTANT NOTICE" AT THE END OF THIS PRESS RELEASE.
STOCKHOLM, March 18, 2025 /...
Themefolio
Profiler
Peergroup
© ActuNews
18.03.2025
OXUR
LISTED
EURONEXT
Oxurion signe une lettre d'intention pour l'acquisition projetée d'une CRO spécialisée en biométrique
News Preview
Louvain, BELGIQUE – 18 mars 2025 – 18h30, Oxurion NV (Euronext Bruxelles : OXUR), entreprise biopharmaceutique basée à Louvain, annonce la signature d'une lettre d'intention (LOI) en vue de l'acquisition projetée d'une participation majoritaire dans une Contract Research Organization (CRO), spé...
Themefolio
Profiler
Peergroup
© ActuNews
18.03.2025
OXUR
LISTED
EURONEXT
Oxurion ondertekent intentieverklaring voor de voorgenomen overname van een CRO gespecialiseerd in biometrie
News Preview
LEUVEN, BELGIË – 18 maart 2025 - 18:30 uur, Oxurion NV (Euronext Brussels: OXUR), een biofarmaceutisch bedrijf met hoofdzetel in Leuven, kondigt de ondertekening aan van een intentieverklaring (LOI) voor de voorgenomen overname van een meerderheidsbelang in een Contract Research Organization (CRO), gespecialiseerd in klinisch databeheer...
Themefolio
Profiler
Peergroup
© ActuNews
18.03.2025
OXUR
LISTED
EURONEXT
Oxurion signs a letter of intent for the planned acquisition of a biometrics-focused CRO
News Preview
Louvain, BELGIUM – March 18, 2025 – 6:30 PM CET, Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, announces the signing of a letter of intent (LOI) for the planned acquisition of a majority stake in a Contract Research Organization (CRO) specialized in clinical data management and biometric anal...
Themefolio
Profiler
Peergroup
© ActuNews
18.03.2025
OXUR
LISTED
EURONEXT
Oxurion ontvangt transparantiekennisgevingen van Atlas Special Opportunities LLC
News Preview
Leuven, BELGIË – 18 maart 2025 – 18u00 CET Oxurion NV (Euronext Brussel: OXUR), een biofarmaceutisch bedrijf met hoofdkantoor in Leuven, België, heeft vandaag aangekondigd dat het, in overeenstemming met de Belgische transparantiewetgeving1, de volgende transparantiekennisgevingen heeft ontvangen:
Oxurion ontving een transpara...
Themefolio
Profiler
Peergroup
© ActuNews
18.03.2025
OXUR
LISTED
EURONEXT
Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC
News Preview
Leuven, BELGIUM – March 18, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notifications as follows:
Oxurion received a transparency notification on March 18, 2025, from Atlas...
Themefolio
Profiler
Peergroup
© PR Newswire
18.03.2025
RAY B
LISTED
STO
Contemplated placement of existing shares in RaySearch Laboratories AB
News Preview
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE OR MAY BE UNLAWFUL. PLEASE REFER TO THE SECTION "IMPORTANT NOTICE" AT THE END OF THIS PRESS RELEASE.
STOCKHOLM, March 18, 2025 /...
Themefolio
Profiler
Peergroup
© PR Newswire
18.03.2025
INTEG B
LISTED
STO
Integrum's OPRA™ Implant System demonstrates superior treatment outcomes in two-year follow-up study by Walter Reed National Military Medical Center
News Preview
MÖLNDAL, Sweden, March 18, 2025 /PRNewswire/ -- Integrum AB (publ) (Nasdaq First North Growth Market: INTEG B) announces today that a newly published independent study from the Walter Reed National Military Medical Center in Bethesda, Maryland, U.S., provides compelling evidence of OPRA™ Implant System's treatment effectiveness in transfemoral am...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.03.2025
KDEV
LISTED
STO
Karolinska Development’s portfolio company Umecrine Cognition provides update on ongoing Phase 1b/2a clinical study
News Preview
STOCKHOLM, SWEDEN – March 18, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has provided an update regarding the ongoing clinical phase 1b/2a trial evaluating the drug candidate golexanolone in PBC patients. Due to technical issues in the production of capsules used in the stu...
Themefolio
Profiler
Peergroup
© PR Newswire
18.03.2025
ATNM
LISTED
XASE
Actinium Pharmaceuticals Announces Clinical Trial Program in Solid Tumors Combining Actimab-A with PD-1 Checkpoint Inhibitors KEYTRUDA® and OPDIVO®
News Preview
- Trials are designed to demonstrate whether the addition of Actimab-A to either KEYTRUDA® or OPDIVO® can result in improved patient outcomes
- MDSCs – Myeloid Derived Suppressor Cells in the tumor microenvironment are believed to reduce effectiveness of PD-1 inhibitors like KEYTRUDA® and OPDIVO®
- Trials supported by preclinica...
Themefolio
Profiler
Peergroup
© PR Newswire
17.03.2025
BIOA B
LISTED
STO
BioArctic receives Orphan Drug Designation for exidavnemab the US
News Preview
STOCKHOLM, March 17, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the US FDA Office of Orphan Products Development (OOPD) has granted orphan drug designation (ODD) to exidavnemab for the treatment of Multiple System Atrophy (MSA), providing incentives for the development of treatments for rare diseases...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.03.2025
GMAB
LISTED
CPH
Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer
News Preview
Media ReleaseCOPENHAGEN, Denmark; March 17, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.03.2025
ORNBV
LISTED
HEL
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
News Preview
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS17 MARCH 2025 at 17.15 EET ...
Themefolio
Profiler
Peergroup
© PR Newswire
17.03.2025
ATNM
LISTED
XASE
Actinium Pharmaceuticals Announces Publication of Actimab-A + CLAG-M Trial Results in Patients with Relapsed or Refractory Acute Myeloid Leukemia in the Peer-Reviewed Journal Leukemia
News Preview
- Median Overall Survival of 18.4 months with Actimab-A + CLAG-M in patients with relapsed or refractory AML who received 1 or 2 lines of prior therapy
- Mutation agnostic potential of Actimab-A demonstrated by high rates of Complete Remissions and Measurable Residual Disease Negativity in patients with high-risk features including TP...
Themefolio
Profiler
Peergroup
© BusinessWire
17.03.2025
DFTX
LISTED
NASDAQ
MindMed Appoints Matt Wiley as Chief Commercial Officer
News Preview
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Matt Wiley as its Chief Commercial Officer (CCO). In his new role, Mr. Wiley will serve as a member of the executive team,...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.03.2025
ATAI
LISTED
NASDAQ
atai Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
News Preview
- Dosed the first patient in the Phase 2 Elumina trial of VLS-01 (buccal film DMT) for patients with treatment-resistant depression; topline data anticipated in Q1’26...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.03.2025
ZEAL
LISTED
CPH
Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity
News Preview
Press release – No. 4 / 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.03.2025
ORNBV
LISTED
HEL
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
News Preview
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS14 MARCH 2025 at 15.30 EET ...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.03.2025
ORY
LISTED
BME
ORYZON to Provide Corporate Progress Updates at Several Events in March-April
News Preview
MADRID, Spain and CAMBRIDGE, Mass., March 14, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give an update on corporate progress at several int...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.03.2025
SKYE
LISTED
NASDAQ
Skye Bioscience to Announce 2024 Financial Results on March 20th, 2025
News Preview
SAN DIEGO, March 14, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will host a conference call on Thursday, March 20th at 1:30 p.m. PT/4:30 p.m. ET to discuss its 2024 fourth quarter and...
Themefolio
Profiler
Peergroup
© PR Newswire
14.03.2025
SECT_B
LISTED
STO
Sectra's nine-month interim report 2024/2025: The industry's most satisfied customers for the twelfth consecutive year
News Preview
LINKÖPING, Sweden, March 14, 2025 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra's (STO: SECT B) enterprise imaging module for radiology is ranked number one by users around the world. We also have the most satisfied customers in digital pathology. Our commitment to customer satisfaction is the foundation of our...
Themefolio
Profiler
Peergroup
© PR Newswire
14.03.2025
SECT_B
LISTED
STO
Sectra's nine-month interim report 2024/2025: The industry's most satisfied customers for the twelfth consecutive year
News Preview
LINKÖPING, Sweden, March 14, 2025 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra's (STO: SECT B) enterprise imaging module for radiology is ranked number one by users around the world. We also have the most satisfied customers in digital pathology. Our commitment to customer satisfaction is the foundation of our...
Themefolio
Profiler
Peergroup
© BusinessWire
13.03.2025
BLUE
LISTED
NASDAQ
BLUEBIRD BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of bluebird bio, Inc. - BLUE
News Preview
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of bluebird bio, Inc. (NasdaqGS: BLUE) to Carlyle Group and SK Capital Partners, LP. Under the terms of the agreement, bluebird shareholders will receive $3.00 per share in cash and a contingent...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.03.2025
ORNBV
LISTED
HEL
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
News Preview
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS13 March 2025 at 16.45 EET ...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.03.2025
GN
LISTED
CPH
Trading in GN Store Nord shares by board members, executives and associated persons
News Preview
GN Store Nord has received notification pursuant to article 19 of regulation (EU) no. 596/2014 of the below transactions related to shares in GN Store Nord made by persons discharging managerial responsibilities in GN Store Nord and/or persons closely associated with them....
Themefolio
Profiler
Peergroup
© Globe Newswire
13.03.2025
KDEV
LISTED
STO
Karolinska Development’s portfolio company AnaCardio has been granted additional EU patent for drug candidate AC01
News Preview
STOCKHOLM, SWEDEN March 13, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company AnaCardio has been granted patent for its drug candidate AC01 as an inotropic agent in the EU....
Themefolio
Profiler
Peergroup
© BusinessWire
13.03.2025
ZLAB
LISTED
NASDAQ
Zai Lab Announces Acceptance of Biologics License Application for TIVDAK for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for TIVDAK (tisotumab vedotin-tftv) for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy.
“In China...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.03.2025
GMAB
LISTED
CPH
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
News Preview
Company Announcement...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.03.2025
GMAB
LISTED
CPH
Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab
News Preview
Company AnnouncementCOPENHAGEN, Denmark; March 12, 2025 – Genmab A/S (Nasdaq: GMAB) Following Genmab A/S’ Annual General Meeting held on March 12, 2025, the Company’s Board of Directors met to constitute itself. Ms. Deirdre P. Connelly was appointed Chair and Ms. Pernille Erenbjerg was appointed Deputy Chair. It was decided to grant 13,926 restrict...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.03.2025
KDEV
LISTED
STO
Karolinska Development's portfolio company PharmNovo receives positive FDA feedback prior to IND application for Phase 2a trial
News Preview
STOCKHOLM, SWEDEN – March 12, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that portfolio company PharmNovo received positive feedback regarding its most advanced drug candidate, PN6047, in a pre-IND meeting with the U.S. Food and Drug Administration (FDA). The meeting aimed to provide guidance on the design of the compa...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.03.2025
GMAB
LISTED
CPH
Passing of Genmab A/S’ Annual General Meeting
News Preview
Company Announcement...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.03.2025
ORNBV
LISTED
HEL
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
News Preview
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS12 March 2025 at 16.15 EET ...
Themefolio
Profiler
Peergroup
© BusinessWire
12.03.2025
ERF
LISTED
EURONEXT
Eurofins Sustainability Services Introduces the Market’s First Offering for Commodity Chemical Testing
News Preview
Eurofins Sustainability Services, a full-service provider for retailers, brands, and manufacturers of consumer products, has grown its extensive service offering to include commodity chemical testing for the softlines industries. With innovative methodology that overcomes the challenges of testing commodity chemicals, this is the first service of...
Themefolio
Profiler
Peergroup
© PR Newswire
12.03.2025
CYRX
LISTED
NASDAQ
Cryoport's MVE Biological Solutions Expands High-Efficiency Cryogenic Freezer Series With Answer to Evolving Needs of Fertility Clinics, Biorepositories and Clinical Laboratories
News Preview
NASHVILLE, Tenn., March 12, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or "the Company"), a global leader in supply chain solutions for the life sciences, today announced the launch of MVE Biological Solutions' ("MVE") High-Efficiency 800 C, the latest addition to its next-generation High-Efficiency ("HE") Series of cryogenic...
Themefolio
Profiler
Peergroup
© PR Newswire
12.03.2025
ATNM
LISTED
XASE
Actinium Pharmaceuticals to Participate at the 37th Annual Roth Conference
News Preview
NEW YORK, March 12, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced it will participate at the 37th Annual Roth Conference on March 16th to 18th....
Themefolio
Profiler
Peergroup
© Globe Newswire
12.03.2025
BAVA
LISTED
CPH
Bavarian Nordic A/S – Notice Convening Annual General Meeting
News Preview
COPENHAGEN, Denmark, March 12, 2025 – Pursuant to Articles 10-14 of the Articles of Association, the shareholders of Bavarian Nordic A/S are hereby convened to the Annual General Meeting to be held on...
Themefolio
Profiler
Peergroup
© PR Newswire
12.03.2025
BIOA B
LISTED
STO
Lars Lannfelt, Pär Gellerfors, and Gunilla Osswald awarded Uppsala University's Innovation and Entrepreneurship Prize
News Preview
STOCKHOLM, March 12, 2025 /PRNewswire/ -- Uppsala University announced today that BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) two founders, Lars Lannfelt and Pär Gellerfors, as well as the company's CEO, Gunilla Osswald, have been awarded the university's Innovation and Entrepreneurship Prize for successfully addressing a growing global heal...
Themefolio
Profiler
Peergroup
© PR Newswire
12.03.2025
BIOA B
LISTED
STO
Lars Lannfelt, Pär Gellerfors, and Gunilla Osswald awarded Uppsala University's Innovation and Entrepreneurship Prize
News Preview
STOCKHOLM, March 12, 2025 /PRNewswire/ -- Uppsala University announced today that BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) two founders, Lars Lannfelt and Pär Gellerfors, as well as the company's CEO, Gunilla Osswald, have been awarded the university's Innovation and Entrepreneurship Prize for successfully addressing a growing global heal...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
